Hims & Hers Health (NYSE:HIMS) Stock Price Down 5.4% - Time to Sell?

Key Points

• Hims & Hers Health's stock fell by 5.4%, trading at $54.74, with a significant decline in trading volume compared to its average session.
• Analysts have issued a range of ratings on the stock, with a consensus rating of "Reduce" and a target price of $38.92.
• Insiders have sold approximately 1.6 million shares of Hims & Hers Health stock in the last ninety days, signaling potential concerns about the company's future performance.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) fell 5.4% on Friday . The company traded as low as $54.24 and last traded at $54.74. 17,406,204 shares changed hands during trading, a decline of 47% from the average session volume of 32,648,639 shares. The stock had previously closed at $57.87.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a report on Saturday, September 27th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Performance

The firm has a fifty day moving average price of $51.57 and a 200 day moving average price of $47.02. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The stock has a market cap of $11.89 billion, a PE ratio of 107.17, a price-to-earnings-growth ratio of 3.91 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the previous year, the company earned $0.06 earnings per share. Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 145,000 shares of the company's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares of the company's stock, valued at $7,139,264.40. This represents a 52.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,622,727 shares of company stock valued at $83,566,691 in the last ninety days. Company insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Virtus Advisers LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at about $26,000. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at about $29,000. Bessemer Group Inc. lifted its stake in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after buying an additional 312 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter valued at about $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its stake in Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.